Inhalable treatment for advanced lung cancer using engineered Influenza A virus
Official title: Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)
Funded at Accurius Therapeutics, INC. · NIH-11166802 · Data updated 2026-11-12
This study is testing a new inhalable treatment for lung cancer that has spread, using a specially designed virus to help your body fight the cancer while keeping healthy cells safe, and it’s aimed at improving survival for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Accurius Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 4R44CA287806-02 |
| Project ID | NIH-11166802 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic non-small cell lung cancer or other cancers that have metastasized to the lungs.
✕Less likely to help
Patients with early-stage lung cancer or those whose cancer has not spread to the lungs may not benefit from this research.
What this research studies
This research focuses on developing a novel inhalable treatment for metastatic non-small cell lung cancer (mNSCLC) and other cancers that have spread to the lungs. The treatment utilizes an engineered oncolytic virus derived from the Influenza A virus, designed to selectively target and destroy cancer cells while preserving healthy cells. The approach aims to enhance the body's immune response against tumors, potentially leading to improved survival rates for patients. The research will involve preclinical studies to identify the most effective virus candidates and assess their efficacy in combination with existing immunotherapies.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking inhalable therapy that significantly improves survival rates for patients with advanced lung cancer.
How similar studies have gone: While the use of oncolytic viruses in cancer treatment is an emerging field, this specific approach using engineered Influenza A virus is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Accurius Therapeutics, INC.
Lexington, United States Active
Researchers
- Principal investigator: Srivatsan, Mallikarjun — Accurius Therapeutics, INC.
- Study coordinator: Srivatsan, Mallikarjun
Related research
Other NIH-funded projects on the same topics.
-
Spatial control of immunogenic cancer killing for locally advanced lung cancer
A new approach uses radiation-triggered nanoparticles to deliver cancer-killing drugs directly to lung tumors while sparing healthy tissue.
-
Predicting how function, thinking, and life quality change in older adults with advanced lung cancer
This project aims to better predict how older adults with advanced non-small cell lung cancer will fare in daily living, thinking, and overall well‑being during treatment.
-
Pathways: a hopeful program to help advanced lung cancer patients pursue personal goals and improve well-being
A brief, hope-based program helps adults with advanced lung cancer stay connected to goals in family, work, and daily life to support mental health and quality of life during treatment.
-
Comprehensive genetic testing for advanced lung cancer
This project looks at how using wide genetic testing that checks hundreds of cancer genes might help people with advanced non-small cell lung cancer and influence care decisions and costs.
-
Brief behavioral support to help breathlessness in advanced lung cancer
A multi-site study tests a short behavioral program delivered by nurses to help adults with advanced lung cancer feel less breathless and more able to do daily activities.
-
Pathways: Supporting Mental Health and Quality of Life for People with Advanced Lung Cancer
This project offers a new program called "Pathways" to help people with advanced lung cancer achieve their personal goals and improve their well-being during treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.